Market Overview

UPDATE: JP Morgan Raises PT to $20 on NuVasive; 2013 Outlook Likely Conservative

Related NUVA
NuVasive Focused On Surgeon Support And Showcasing Industry-Leading Products At North American Spine Society 29th Annual Meeting
Benzinga's Top Downgrades

JP Morgan maintained NuVasive (NASDAQ: NUVA) with a Neutral rating and raised the price target from $17.00 to $20.00.

JP Morgan noted, "After taking into account expected contributions from both the PCM cervical disc ($3-5M) and Japan ($10M), where Nuvasive recently launched, management's $655M forecast implies growth of just 3-4% from the company's base business. This strikes us as overly conservative, coming on the heels of a better-than-feared 4Q performance, and likely reflects management's desire to set a low bar following three straight years of volatile performance from the business."

NuVasive closed at $17.27 on Monday.

Latest Ratings for NUVA

Dec 2014Brean CapitalReiteratesBuy
Nov 2014Wells FargoUpgradesMarket PerformOutperform
Nov 2014BarclaysMaintainsEqual-weight

View More Analyst Ratings for NUVA
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Price Target Analyst Ratings


Related Articles (NUVA)

Around the Web, We're Loving...

Get Benzinga's Newsletters